Successful engraftment is highly dependent on the quality and quantity of stem cells and nucleated cells in cord blood. Storage of umbilical cord blood is expensive and it will be very useful if factors that influence cell count and viability could be identified to aid in the decision to process and store cord blood collections for the ultimate aim of successful engraftment. This study determined the standards for laboratory parameters of haematopoietic potential, such as collection volume, post processing volume, CD34+/45+ cell counts and viability of stem cells and leukocytes and cell ratios for the cord blood bank. In this research we determined whether maternal age and infant gender have an effect on laboratory parameters. We studied the effect of 4°C and room temperature (RT) as well as the period of storage on the same laboratory parameters. The quality and recovery of stem cells and leukocytes after laboratory manipulation was determined. Established standards for leukocyte count, stem cell count and collection volume compare well with other international UCB banks. Maternal age and infant gender have no influence on laboratory parameters and could therefore not be used as a measure of cell quantity and quality prior to processing. Cell count and cell viability of stem cells is not significantly influenced by 4°C or RT temperature or 24h and 48h storage. Leukocyte cell count and viability is not affected by storage temperature, but increased storage periods showed high levels of leukocyte cell count deterioration and decreased leukocyte cell viability. Processing of UCB causes significant cell loss in stem cells and leukocytes. Processing or no processing of UCB has showed no affect on the viability of stem cells stored at different storage periods and temperature. Temperature has no affect on leukocyte cell counts and viability of either processed or unprocessed leukocytes but increased storage periods dramatically decrease leukocyte count and viability. The information generated by this study will assist in the process of optimizing the storage of UCB. Copyright / Dissertation (MSc)--University of Pretoria, 2010. / Immunology / unrestricted

Thesis (Master, Microbiology & Immunology) -- Queen's University, 2013-09-30 22:46:35.072

No description available.

Platelet- and plasma-derived factor Va are absolutely essential for thrombin generation catalyzed by the prothrombinase complex, a 1:1 stoichiometric complex of the serine protease factor Xa and the nonenzymatic cofactor, factor Va, assembled on an appropriate membrane surface in the presence of calcium ions. Two whole blood pools of the procofactor, factor V, exist: approximately 75% circulates in the plasma as a single chain inactive molecule, while the other 25% resides in platelet α-granules in a partially proteolytically-activated state. Our laboratory demonstrated that the platelet-derived cofactor originates following endocytosis of plasma-derived factor V by megakaryocytes, the platelet precursor cells, via a two receptor system including an uncharacterized, specific factor V receptor and low density lipoprotein receptor related protein-1. Following endocytosis factor V is physically and functionally modified and trafficked to the platelet α-granule from where it is released upon platelet activation at sites of vascular injury. The first goal of this dissertation was to define how factor V endocytosis changes over the course of megakaryocyte development. Hematopoietic multipotential stem cells were isolated from human umbilical cord blood and subjected to ex vivo differentiation into megakaryocytes. Megakaryocyte differentiation was assessed by flow cytometry using fluorescently-labeled antibodies against megakaryocyte- and platelet-specific markers and factor V directly conjugated to a fluorophore over 12 days. Differentiation was confirmed by a decrease in a stem cell marker (CD34) and an increase in a mature megakaryocyte marker (CD42) and coincident with factor V endocytosis. Live cell imaging verified differentiation and permitted the observation of proplatelet formation, the precursor to circulating platelets. Analogous experiments verified the trafficking of factor V into proplatelet extensions. Factor V is a highly glycosylated protein: potential roles of these glycans may be endocytosis and trafficking by megakaryocytes. We previously demonstrated that factor V endocytosis is mediated by the light chain region of the procofactor. This region of factor V contains three glycans - one high mannose and two complex N-linked glycans. In the second part of this dissertation, a role for the complex N-linked glycans at Asn1675 and Asn2181 of the factor V light chain in factor V endocytosis by megakaryocytes was assessed. Exoglycosidases were used to selectively trim the complex N-linked glycans on human factor V under native conditions. Treatment with neuraminidase removed 100% of the sialic acid residues on the factor V light chain as demonstrated by gel electrophoresis and mass spectrometry. Treatment with β-1,4-galactosidase removed 69% of the galactose residues at Asn1675 and 100% at Asn2181. Glycosidase-treated factor Va behaves similarly to untreated factor Va in thrombin generation assays suggesting that cofactor activity is unaltered by glycan trimming. In addition, glycan removal had no effect on factor V endocytosis by megakaryocyte-like cells. These observations suggest that complex N-linked glycans on the factor V light chain are not important for factor Va cofactor activity or factor V endocytosis by megakaryocyte-like cells, which strongly suggests that they have a role in trafficking.

Spinal cord injury (SCI) pathophysiology occurs as a primary traumatic event followed by secondary injury, resulting in the loss of neurons, oligodendrocytes and demyelination of residual axons. Unfortunately, endogenous spontaneous regeneration of oligodendrocytes is minimal. Previously, a method to generate multi-potential stem cells (MPSC) from umbilical cord blood (UCB) has been reported using lineage negative cells (Linneg) grown in fibroblast growth factor 4 (FGF4), stem cell factor (SCF) and fms-like tyrosine kinase receptor-3 ligand (Flt-3l) supplemented serum free medium. These MPSC have the ability to differentiate into bone, muscle and endothelial cells. In this thesis, the ability of MPSC to differentiate into oligodendrocytes was investigated as a potential treatment for SCI. Culturing MPSC under conditions that mimic normal timing of oligodendrocyte differentiation resulted in cells that expressed oligodendrocyte markers in vitro and were morphologically similar to them. I next investigated the ability of MPSC to improve functional recovery in a SCI compression injury model. Although the cells did not differentiate into oligodendrocytes in vivo as we initially hypothesised, a modest but significant improvement in hindlimb function was observed. A cytokine assay revealed that MPSC secrete elevated levels of anti-inflammatory, angiogenic and neurotrophic factors, possibly contributing to indirect mechanisms of repair by reducing secondary injury. Shiverer mouse neonates were next used as an alternative non-injury model to investigate the differentiation potential of MPSC. We hypothesised that transplanting MPSC into a host with an immature immune system and an actively myelinating environment would lead to engraftment and differentiation into oligodendrocytes. However no MPSC that differentiated into oligodendrocytes could be detected. Altogether, our in vitro data adds support for the reprogramming of cells, with further studies needed to test the functionality of resulting oligodendrocyte-like cells. Although MPSC failed to differentiate in both in vivo models, several potential therapeutic targets to treat SCI were found.

Spinal cord injury (SCI) pathophysiology occurs as a primary traumatic event followed by secondary injury, resulting in the loss of neurons, oligodendrocytes and demyelination of residual axons. Unfortunately, endogenous spontaneous regeneration of oligodendrocytes is minimal. Previously, a method to generate multi-potential stem cells (MPSC) from umbilical cord blood (UCB) has been reported using lineage negative cells (Linneg) grown in fibroblast growth factor 4 (FGF4), stem cell factor (SCF) and fms-like tyrosine kinase receptor-3 ligand (Flt-3l) supplemented serum free medium. These MPSC have the ability to differentiate into bone, muscle and endothelial cells. In this thesis, the ability of MPSC to differentiate into oligodendrocytes was investigated as a potential treatment for SCI. Culturing MPSC under conditions that mimic normal timing of oligodendrocyte differentiation resulted in cells that expressed oligodendrocyte markers in vitro and were morphologically similar to them. I next investigated the ability of MPSC to improve functional recovery in a SCI compression injury model. Although the cells did not differentiate into oligodendrocytes in vivo as we initially hypothesised, a modest but significant improvement in hindlimb function was observed. A cytokine assay revealed that MPSC secrete elevated levels of anti-inflammatory, angiogenic and neurotrophic factors, possibly contributing to indirect mechanisms of repair by reducing secondary injury. Shiverer mouse neonates were next used as an alternative non-injury model to investigate the differentiation potential of MPSC. We hypothesised that transplanting MPSC into a host with an immature immune system and an actively myelinating environment would lead to engraftment and differentiation into oligodendrocytes. However no MPSC that differentiated into oligodendrocytes could be detected. Altogether, our in vitro data adds support for the reprogramming of cells, with further studies needed to test the functionality of resulting oligodendrocyte-like cells. Although MPSC failed to differentiate in both in vivo models, several potential therapeutic targets to treat SCI were found.

No description available.

A utilização das células progenitoras hematopoéticas (CPH) obtidas do sangue de cordão umbilical e placentário (SCUP) apresenta vários benefícios para o transplante de CPH em comparação às células provenientes de outras fontes. Dentre eles, a maior disponibilidade e a maior imaturidade imunológica das CPH, o que permite certa flexibilidade nos critérios de compatibilidade entre doador e receptor e uma menor taxa de reação do enxerto-versus-hospedeiro. A legislação brasileira e órgãos internacionais exigem a realização de vários testes para garantir a qualidade do produto hemoterápico contendo CPH a ser transplantado. O objetivo deste estudo foi confirmar que o teste para quantificação de CPH com elevada atividade da enzima ALDH1(ALDHbr) pode ser considerado um teste de adequado ou seja, é capaz de predizer quais produtos tem melhor capacidade de repopular a medula óssea do recipiente após o transplante. Para isso, foram utilizadas 40 unidades de SCUP coletadas e processadas pelo Banco de Sangue de Cordão Umbilical e Placentário do Cetebio / Fundação Hemominas. As unidades foram processadas por método automatizado e amostras do creme leucocitário (buffy coat) foram coletadas para a realização da quantificação de células ALDHbr, quantificação de células CD34+, ensaio clonogênico (CFU), hemograma e cálculo do total de células nucleadas (TCN). A citometria de fluxo foi utilizada para a quantificação das CPH ALDHbr e CD34+ e das subpopulações CD45dim e CD38+. Outras informações como idade materna, idade gestacional e sexo do recém-nascido também foram coletadas para descrição das unidades. Para verificar a viabilidade da utilização do teste de ALDH pelos BSCUP foi realizado o levantamento do seu custo. A capacidade funcional das CPH em proliferar e se diferenciar em tecido hematopoético foi avaliada por meio do ensaio clonogênico. Detectou-se correlação entre a quantidade de células ALDHbr e o número de colônias no ensaio clonogênico (p<0,001), entre o número de células ALDHbr e de células CD34+ (p=0,001) e entre o número de colônias no ensaio clonogênico e o número de células CD34+ (p<0,001). A imunofenotipagem mostrou que 46,25% das células ALDHbr eram CD45dimCD38+CD34+. Os dados sugerem que a quantificação de células ALDHbr em unidades de SCUP pode ser considerada teste adequado, de baixo custo, de execução simples, rápida e menos dependente do operador em relação ao ensaio clonogênico. / The use of the umbilical cord blood cells presents numberless benefits when compared to the cells from different sources. Among them, the ease of availability, the bigger immunological immaturity, which allows some flexibility in the compatibility between donor and receptor and less induction of reaction of graft-versus-host. The Brazilian legislation and international organizations demand the practice of various tests to guarantee the quality of the product to be transplanted. The aim of this research was to confirm that the test used to quantify ALDHbr cells can be considered a power test, meaning that it tests the ability to repopulate the bone marrow after transplant. For this study, it has been used 40 units of SCUP collected and processed by the Cetebio Umbilical Cord Blood Bank - Fundação Hemominas. The units were processed by the automatized method and the samples of the final product (buffy coat) were collected for the quantification of ALDHbr cells, quantification of CD34+ cells, clonogenic essay (CFU), hemogram and the total number of nucleated cells (TNC). It was used the flow cytometry to perform ALDH and CD34+ tests. Besides that, it was also performed the association of antibodies anti-CD34, anti-CD45 and anti-CD38 for the immunophenotyping of the units. Other information such as maternal age, fertilization age and the newborn gender were also collected for description of the units. In order to verify the viability of the use of the ALDH test by BSCUP its costs were calculated, as well as of the clonogenic essay. The results showed a significant correlation between ALDHbr cells and the clonogenic essay (p<0.001), between ALDHbr and CD34+ cells (p=0,001) and between the clonogenic essay and the quantification of CD34+ cells (p<0,001). The immunophenotyping revealed that 46,25% of ALDHbr cells were CD45dimCD38+CD34+. The data indicated that the quantification of ALDHbr cells in the SCUP units can be considered a powerful and low cost procedure, of easier and quicker execution and less operator dependent.

A utilização das células progenitoras hematopoéticas (CPH) obtidas do sangue de cordão umbilical e placentário (SCUP) apresenta vários benefícios para o transplante de CPH em comparação às células provenientes de outras fontes. Dentre eles, a maior disponibilidade e a maior imaturidade imunológica das CPH, o que permite certa flexibilidade nos critérios de compatibilidade entre doador e receptor e uma menor taxa de reação do enxerto-versus-hospedeiro. A legislação brasileira e órgãos internacionais exigem a realização de vários testes para garantir a qualidade do produto hemoterápico contendo CPH a ser transplantado. O objetivo deste estudo foi confirmar que o teste para quantificação de CPH com elevada atividade da enzima ALDH1(ALDHbr) pode ser considerado um teste de adequado ou seja, é capaz de predizer quais produtos tem melhor capacidade de repopular a medula óssea do recipiente após o transplante. Para isso, foram utilizadas 40 unidades de SCUP coletadas e processadas pelo Banco de Sangue de Cordão Umbilical e Placentário do Cetebio / Fundação Hemominas. As unidades foram processadas por método automatizado e amostras do creme leucocitário (buffy coat) foram coletadas para a realização da quantificação de células ALDHbr, quantificação de células CD34+, ensaio clonogênico (CFU), hemograma e cálculo do total de células nucleadas (TCN). A citometria de fluxo foi utilizada para a quantificação das CPH ALDHbr e CD34+ e das subpopulações CD45dim e CD38+. Outras informações como idade materna, idade gestacional e sexo do recém-nascido também foram coletadas para descrição das unidades. Para verificar a viabilidade da utilização do teste de ALDH pelos BSCUP foi realizado o levantamento do seu custo. A capacidade funcional das CPH em proliferar e se diferenciar em tecido hematopoético foi avaliada por meio do ensaio clonogênico. Detectou-se correlação entre a quantidade de células ALDHbr e o número de colônias no ensaio clonogênico (p<0,001), entre o número de células ALDHbr e de células CD34+ (p=0,001) e entre o número de colônias no ensaio clonogênico e o número de células CD34+ (p<0,001). A imunofenotipagem mostrou que 46,25% das células ALDHbr eram CD45dimCD38+CD34+. Os dados sugerem que a quantificação de células ALDHbr em unidades de SCUP pode ser considerada teste adequado, de baixo custo, de execução simples, rápida e menos dependente do operador em relação ao ensaio clonogênico. / The use of the umbilical cord blood cells presents numberless benefits when compared to the cells from different sources. Among them, the ease of availability, the bigger immunological immaturity, which allows some flexibility in the compatibility between donor and receptor and less induction of reaction of graft-versus-host. The Brazilian legislation and international organizations demand the practice of various tests to guarantee the quality of the product to be transplanted. The aim of this research was to confirm that the test used to quantify ALDHbr cells can be considered a power test, meaning that it tests the ability to repopulate the bone marrow after transplant. For this study, it has been used 40 units of SCUP collected and processed by the Cetebio Umbilical Cord Blood Bank - Fundação Hemominas. The units were processed by the automatized method and the samples of the final product (buffy coat) were collected for the quantification of ALDHbr cells, quantification of CD34+ cells, clonogenic essay (CFU), hemogram and the total number of nucleated cells (TNC). It was used the flow cytometry to perform ALDH and CD34+ tests. Besides that, it was also performed the association of antibodies anti-CD34, anti-CD45 and anti-CD38 for the immunophenotyping of the units. Other information such as maternal age, fertilization age and the newborn gender were also collected for description of the units. In order to verify the viability of the use of the ALDH test by BSCUP its costs were calculated, as well as of the clonogenic essay. The results showed a significant correlation between ALDHbr cells and the clonogenic essay (p<0.001), between ALDHbr and CD34+ cells (p=0,001) and between the clonogenic essay and the quantification of CD34+ cells (p<0,001). The immunophenotyping revealed that 46,25% of ALDHbr cells were CD45dimCD38+CD34+. The data indicated that the quantification of ALDHbr cells in the SCUP units can be considered a powerful and low cost procedure, of easier and quicker execution and less operator dependent.

Alzheimer's disease (AD) is the most prevalent form of progressive dementia and is characterized by the accumulation of amyloid beta (Aß) peptide in the brain and in the cerebral vessels forming cerebral amyloid angiopathy (CAA). As previously reported, an active immunization strategy of mice with Aß1-42 peptide results in decreased Th1 and increased Th2 cytokine responses as well as an effectively clearance of CNS Aß. This approach has also yielded favorable results for many patients, unfortunately, a small percentage of these study participants developed severe aseptic meningoencephalitis likely secondary to CNS invasion of activated T-cells. We have previously demonstrated that disruption of CD40-40L pathway reduces Aß plaque load, promotes Th2 response, and rescues from cognitive impairments. However, direct blockage of the CD40 pathway by passive vaccination with anti-CD40L antibody leads to immunosupression. Therefore, in its current form this therapeutic strategy poses an unacceptable risk to the recipient of treatment, aged individual. For those reasons, the identification and characterization of alternative modulators/inhibitors of CD40 signaling may be necessary for the development of safe and effective AD immunotherapy. This proposal introduces novel immunomodulatory therapies that are based on previous vaccination strategies or cell based therapies across medial field. We showed that transcutaneous vaccination can both be efficacious and safe, thus clearly demonstrating that the right combination of the antigens, adjuvants, and the routes of administration are crucial for the right vaccine. Furthermore, we demonstrated that the effects of current Aß vaccine strategies could be enhanced by a simultaneous blockade of CD40-40L signaling. As an alternative approach, we explored the possibility of cell-based therapies and showed that human umbilical cord blood cells, which are currently used as a treatment for systemic lupus erythematosus and leukemia, and currently investigated against stroke, amyotropic lateral sclerosis, age-related macular degeneration, multiple sclerosis, and Parkinson's disease, and showed that not just they improved the AD like pathology in transgenic animals but altered both the brain and peripheral inflammation levels. Lastly, we discussed the involvement of microglia, one of the key players in both AD pathogenesis and Aß clearance and suggesed that microglia in actuality has a continuum of physiological activation states that contribute to proinflammation, antiinflammation, and phagocytosis.